// App-Quantinova.ai

EP353 : A REGISTRY-BASED, OBSERVATIONAL SAFETY STUDY OF INOTUZUMAB OZOGAMICIN (INO) IN PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PROCEEDING TO HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT)

Researchers

Presenter

  • David Marks

Principal Investigators

  • Marcos de Lima

  • Partow Kebriaei

  • Francesco Lanza

  • Christina Cho

  • Sergio Giralt

  • Gizelle Popradi

  • Michael T Hemmer

  • Xin Zhang

  • Richa Shah

  • Verna Welch

  • Erik Vandendries

  • Matthias Stelljes

  • Wael Saber

Medical Centers

  • CIBMTR,Medical College of Wisconsin,Milwaukee, WI,United States

  • Pfizer Inc,Cambridge,United States

  • Universitatsklinikum Munster, Munster, Germany

  • Memorial Sloan-Kettering Cancer Center, New York, NY, United States

  • 7Cleveland VA Medical Center Cleveland OH United States

  • Pfizer Inc,Shanghai,China

  • Ospedale di Ravenna, Ravenna, Italy

  • Pfizer Inc., New York, United States

  • McGill University Health Centre, Montreal, QC, Canada

  • University of Texas MD Anderson Cancer Center, Houston, Texas, United States

  • University of Bristol, Bristol, United Kingdom

Locations

  • United States

  • Germany

  • China

  • Italy

  • Canada

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • Breakpoint Cluster Region

Drug/Treatment

  • Inotuzumab ozogamicin

Outcome

  • N/A

Study Design

  • Observational

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved